Search PubMed⌕ Search

Biomedical subjects

R M Schimpff

Publications and source records attributed to R M Schimpff.

At least 73 records · Page 4Linked to original sources
PubMed1980

[Early effects of intramuscular growth hormone on plasma somatomedin activity (author's transl)].

The early effects of intramuscular injection of human growth hormone (hGH) on plasma sulfation activity (Sm) have been followed for 72 hours: 1) after one injection of 6 mg in control children and in pituitary dwarfs (isolated idiopathic GH deficiency, multiple idiopathic pituitary deficiencies, and post-surgical or post-radiotherapic hypopituitarism); 2) after 6 injections of 1 mg every 12 hours in idiopathic pituitary dwarfs. Following injection of 6 mg, Sm decreases during 2-4 hours in all groups studied, then rises and peaks at 24 hours. The early decrease of Sm could relate to a rise of Sm-binding protein, as suggested by data obtained in the dog after intravenous injection of bovine GH. Following 6 injections of 1 mg, the rise of Sm is slower but higher and more protracted than with one injection of 6 mg. This fact suggests that the clinical effects of fractionation of treatment with HGH require further study. The lack of correlation between the biological data obtained and the clinical effects of hGH treatment upon the growth of pituitary dwarfs shows that the short-term hGH test used does not allow to foresee the effects of treatment.

Adolescent↗
PubMed1978

Early paradoxical decrease in serum somatomedin activity following injection of growth hormone.

The early effects have been investigated of an intra-muscular growth hormone injection (6 mg/m2) on serum somatomedin activity in 21 children with growth hormone deficiency and in 5 children with constitutional short stature. In cases of hGH total deficiency, there was an early and significant decrease in SM activity, which reached a minimum level 2 hours after the injection (-34% p less than 0.01). After 24 hours, SM activity increased to +64% above basal levels. In cases of hGH partial deficiency and in short, non-hGH deficient children, no similar early changes were observed. Neither was any correlation found between the variations in SM activity and those in hGH or free fatty acid levels. The unexpected early decrease in SM activity following hGH administration seems to be related to GH deficiency.

Child↗
PubMed1978

Serum somatomedin activity measured as sulphation factor in peripheral, hepatic and renal veins of patients with alcoholic cirrhosis.

Serum somatomedin (SM) activity, measured as sulphation factor on chick embryo cartilage, and growth hormone (GH) levels were measured in peripheral, hepatic and renal veins of 23 patients with a alcoholic cirrhosis. SM activity (mean +/- SEM) was 0.65 +/- 0.05 U/ml in peripheral vein, 0.59 +/- 0.04 U/ml in hepatic vein, and 0.74 +/- 0.07 U/ml in renal vein. Mean GH levels were respectively 2.8, 2.5 and 3.1 ng/ml. Compared to peripheral vein, SM increase in renal vein was 19% (P less than 0.05). Serum SM activity was significantly lower in 13 patients with alcoholic hepatitis associated with cirrhosis than in other 10 patients (P less than 0.02 in hepatic blood and P less than 0.05 in peripheral blood). The decrease of SM activity seems related to cytolysis and hepato-cellular insufficiency. At last, in patients with alcoholic hepatitis, SM activity was lower in the hepatic vein than in the peripheral vein (P less than 0.05). The cause of this difference remains under discussion, no SM inhibitors being found in the serum samples used in this study.

Adult↗
PubMed1977

Serum somatomedin activity depressed after glucagon administration in man.

The variations in serum somatomedin (SM) activity were compared in 14 subjects after glucagon injection (1 mg im), and in 10 controls. A significant decrease in SM activity was observed 30 and 60 min after glucagon (p less than 0.01 to less than 0.001) whereas no significant change was noted in the controls. Analysis of the dose-response curves suggests that this decrease reflects depressed SM concentration. No correlation was found between the variations of growth hormone (GH), cortisol, or fatty acids and those of SM activity. The maximum variations in glycemia, insulin and SM activity occured during the same time interval. These results suggest that glucagon may play some role in the regulation of circulating SM.

Child↗
PubMed1976

The inhibitory effect of hydrocortisone on the chicken embryo cartilage somatomedin assay.

In a study of the effects of hydrocortisone on the embryonic chicken cartilage somatomedin assay, in the absence and in the presence of normal human reference serum (NHRS), it was found that: (1) The basal uptake of 35S into chicken embryo pelvic cartilage was reduced when hydrocortisone hemisuccinate was added to the incubation medium in concentrations ranging from 1.5 to 1.5 X 10(5) ng/ml. There was a correlation between the inhibitory effect and the quantity of hydrocortisone added (r=-0.869; p less than 0.01). (2) The 35S uptake stimulated by 1.25 and 5% serum present in the incubation medium was reduced by hydrocortisone in a final concentration range of 150-1.5 X 10(5) ng/ml incubation medium. The minimal dose was 1,000 times that required to affect the basal 35S uptake. (3) When hydrocortisone was directly added to the NHRS, its interfering effect on the 35S uptake stimulated by 1.25, 5 and 20% of serum in the incubation medium was demonstrable with 5 X 10(5) ng hydrocortisone/ml serum. This concentration exceeded the physiological level of hydrocortisone by a factor of 5,000.

Animals↗
PubMed1976

The liver as a source of somatomedin.

Somatomedin (Sm) activity (measured by [35S] utake in chick embryo cartilage) was determined in serum samples simultaneously drawn from the hepatic vein, portal vein, femoral artery and demoral vein of seventeen anaesthezied normal adult dogs). A pool of human serum was taken as reference (Sm = 1 U/ml). Sm levels in the peripheral vein of dogs were 0.38 +/- 0.03 U/ml). Mean +/- SEM). Sm activity was greater in the hepatic vein (0.48 U/ml) than in the other vessels (0.36, 0.39, 0.38 U/ml), and the paired differences were significant (P less than 0.002 to P less than 0.05). In three dogs which received b-GH (20 IU/day), the Sm levels were significantly increased after nine days in the femoural vein (P less than 0.05) and in the hepatic vein (P less than 0.05). The validity of the assay is discussed; a possible interference of NEFA in the assay is eliminated. The difference of Sm levels between hepatic and portal veins, related to hepatic flow measured in seven of these dogs, indicate an important production of Sm by the liver.

Animals↗
PubMed1970

[Cerebral gigantism].

Explore the source record for details and available documents.

Age Determination by Skeleton↗